Silence Therapeutics plc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
SLN$19.79+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cashflows
| Year ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Cash flow from operating activities | |||
| Net loss | $(45,309) | $(54,228) | $(50,334) |
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | |||
| Depreciation expense | 336 | 369 | 379 |
| Amortization expense | 257 | 252 | 217 |
| Share-based compensation expense | 16,307 | 16,274 | 12,686 |
| Net foreign exchange impacts | (2,581) | 3,962 | (1,003) |
| Other income | (4,472) | (1,803) | (280) |
| Income tax expense | 845 | 956 | 688 |
| Change in operating assets and liabilities: | |||
| (Increase)/decrease in trade receivables | (904) | 392 | (723) |
| (Increase)/decrease in other current assets | (1,330) | 1,955 | (5,199) |
| Increase in R&D benefit receivable | (2,337) | (3,403) | (9,821) |
| Decrease/(increase) in other long-term assets | - | (3,217) | - |
| Increase/(decrease) in trade and other payables | 499 | (473) | 2,024 |
| Decrease in contract liabilities | (28,786) | (10,323) | (5,443) |
| Decrease in operating lease liabilities | (165) | (175) | (235) |
| Net cash (used in) provided by operating activities | (67,640) | (49,462) | (57,044) |
| Cash flow from investing activities | |||
| Redemption of term deposits | 117,412 | 45,121 | - |
| Purchase of term deposits | (139,167) | (25,771) | (19,953) |
| Purchase of property, plant and equipment | (211) | (56) | (173) |
| Purchase of intangible assets | - | - | (372) |
| Net cash (used in) provided by investing activities | (21,966) | 19,294 | (20,498) |
| Cash flow from financing activities | |||
| Proceeds from issue of ordinary shares | 142,087 | 31,937 | 52,581 |
| Net cash provided by financing activities | 142,087 | 31,937 | 52,581 |
| Increase/(decrease) in cash and cash equivalents | 52,481 | 1,769 | (24,961) |
| Cash and cash equivalents at start of period | 68,789 | 66,271 | 99,351 |
| Effect of exchange rate fluctuations on cash and cash equivalents held | 60 | 749 | (8,119) |
| Cash and cash equivalents at end of period | $121,330 | $68,789 | $66,271 |
| Supplemental disclosures of cash flow information: | |||
| Tax Paid | (433) | (801) | - |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.